China’s CMT To Buy HPV Diagnostics From Firm For $345 Million
This article was originally published in PharmAsia News
Executive Summary
China Medical Technologies says it has bought from a diagnostics maker the rights to market a human papillomavirus detection system for $345 million. The system consists of a biosensor chip for HPV-DNA able to identify 24 common strains. The chip was developed by Molecular Diagnostic Technologies, which has agreed to sell the technology to China Medical around the end of the year. China estimate 30 percent of the 120 million Chinese women who should have tests for cervical cancer would need HPV tests, a business it figures could reach $700 million a year. (Click here for more
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.